Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...

Celltrion receives US FDA approval of 300mg strength of Omlyclo, the first and only interchangeable biosimilar to Xolair: Incheon, South Korea Thursday, December 4, 2025, 11:00 Hr ...

The FDA's approval of the new dosing option for Omlyclo addresses the diverse needs of patients with allergic and ...

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

Celltrion secures US approval for 300mg OMLYCLO syringe, completes full PFS lineup Celltrion completes omalizumab prefilled ...

Susan Ringdal EVP, Strategic Planning and Global Affairs +44 (0)20 7399 2760/ +44 7776 477050 Steven Weiss US Communications +1 732 788 8279 ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages ...

First anthrax vaccine developed using recombinant DNA technology- Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC ...

The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled ...

Managing polymer melts and temperature variations is key to achieving product quality and operational efficiency.

Use an AI browser? 5 ways to protect yourself from prompt injections - before it's too late ...

On Friday, the F.D.A. approved a new antibiotic, zoliflodacin, a day after an article published in The Lancet reported that a ...